Sign in
CompletedNo phase

Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia

Key facts

Who runs it
MindAhead UG
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
50 people enrolled
Started
21 Dec 2023
Ended
31 Oct 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MindAhead Active
  • Treatment-as-usual
Record updated
13 November 2024

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Diagnosis of cognitive impairment in MCI stage (ICD-10 codes: F06.7, F07.8) or mild dementia stage (ICD-10: F00.-*, F01.-, F03) due to all etiologies apart from etiologies described in F02.- (Pick's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, HIV, Lewy body disease). Hence, etiologies of MCI and mild dementia include; Alzheimer's disease (e.g., F00.-*); Vascular disease (e.g., F01.-) (exception in case of stroke: event occurred > 12 months ago without ongoing spontaneous remission); Mixed diseases; Unclear etiologies
  • MCI or mild dementia diagnosis assigned within the last 12 months by a neurologist or psychiatrist from our cooperation partners that fulfil adequate diagnosis procedures such as neuropsychological assessment, brain imaging, self- and/or third-party medical history interview, and potentially cerebrospinal fluid, positron emission tomography, or electrophysiological measures
  • MCI or mild dementia diagnosis confirmed by a treating physician
  • MMSE ≥ 24 or MoCA ≥ 18 (last date of assessment is decisive; needs to be within the last 12 months)
  • Sufficient physical fitness to engage in physical activities (e.g., walking or cycling) as confirmed by a treating physician
  • Age ≥ 50
  • German language skills sufficient to understand German instructions of study assessments and of the intervention
  • Ability and sufficient vision to operate a smartphone

Who cannot take part

  • possibly moderate or severe cognitive impairment (moderate or severe dementia), indicated by MMSE < 24 or MoCA < 18 (last date of assessment is decisive; needs to be within the last 12 months)
  • Specific brain injury events within the last 12 months or with ongoing spontaneous remission due to; Stroke (ischemic, hemorrhagic); Traumatic brain injury
  • Specific etiologies of MCI or mild dementia (F02.-) that show a variable course or a fast progression including; Multiple sclerosis; Parkinson's disease; Pick's disease / Frontotemporal lobar degeneration; Lewy body disease; Brain tumors; Autosomal dominant form of Alzheimer's disease with early first manifestation; Creutzfeldt-Jakob disease
  • German language restrictions or visual restrictions which prevent from understanding written German instructions of assessment or intervention procedures (e.g. severe aphasia, lack of sufficient German language skills, severe non-corrected visual impairment)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This pilot study investigates effects of a digital behavioral activation therapy in treating patients with mild cognitive impairment and mild dementia, applying a randomized controlled parallel group design. The primary goal is to estimate effect sizes for a larger trial. A further aim is to investigate the feasibility of study procedures and to validate new questionnaire scores. Primary outcomes are the change in the patients' quality of life and in their overall activity level.

The 2 groups in the trial

  • MindAhead + TAU GroupTreatment being tested

    The intervention group receives the digital health app MindAhead Active for 3 months as well as treatment-as-usual (TAU, see Control intervention).

    Treatment: MindAhead Active and Treatment-as-usual

  • TAU GroupExisting treatment, for comparison

    The control group receives TAU which may include antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins depending on clinical findings.

    Treatment: Treatment-as-usual

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with Mild Cognitive Impairment or Mild Dementia: a Monocentric Randomized Controlled Pilot Trial (MindMoments-Pilot)
Record updated
13 November 2024